Comments
Biological E Limited (BE) has entered into an agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical companies under the Johnson & Johnson umbrella, for a Covid-19 vaccine candidate.
The pact is for the creation/enhancement of manufacturing capacities for drug substance and product for Johnson & Johnson’s Covid-19 vaccine candidate, Ad26.COV2.S.
Johnson & Johnson’s vaccine candidate is currently in Phase 1/2a clinical trials.
“Given the magnitude of the Covid-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration,” Mahima Datla, Managing Director, BE, said in a release on Thursday.
“We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson’s commitment to global access for its Covid-19 vaccine,” said Narender Dev Mantena, Director of BioE Holdings Inc, who heads BE’s novel vaccine initiative.
Hyderabad-based BE supplies vaccines to over 100 countries and its therapeutic products are sold in India and the US. BE currently has eight WHO-prequalified vaccines in its portfolio.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.